Point72 Hong Kong LTD Allakos Inc. Transaction History

Point72 Hong Kong LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$3.02 - $6.12 $2,144 - $4,345	710 New	710 $4,000
Q1 2022 May 16, 2022	SELL	$5.08 - $9.81 $68,940 - $133,131	-13,571 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$8.55 - $111.89 $116,032 - $1.52 Million	13,571 New	13,571 $133,000
Q3 2021 Nov 15, 2021	SELL	$76.53 - $110.43 $26,632 - $38,429	-348 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$85.37 - $114.1 $29,708 - $39,706	348 New	348 $30,000
Q2 2020 Aug 14, 2020	SELL	$44.04 - $80.69 $5,769 - $10,570	-131 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$44.49 - $93.39 $5,828 - $12,234	131 New	131 $6,000

68.8M

20.9K

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $24.6M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

Get notified when there are updates to the investment portfolio of Point72 Hong Kong LTD, based on Form 13F filings with the SEC.

Stay updated on Point72 Hong Kong LTD with notifications on news.